Systematic review reveals rebound hypercalcemia in osteoporosis after denosumab withdrawal, suggesting new treatment protocols.
Hypercalcemia after denosumab withdrawal in osteoporosis is rare, typically mild, and reflects rebound osteoclast activation. Sequential antiresorptive therapy is strongly recommended following denosumab discontinuation.
No takes yet. Share an insight, caveat, or question.
Menéndez et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: